Pacific Edge (ASX:PEB) EBITDA: A$-32.03 Mil (TTM As of Mar. 2026)


ASX:PEB Pacific Edge Ltd ASX:PEB
42 GF Score
Price A$0.25
GF Value A$0.05
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Pacific Edge EBITDA?

Pacific Edge ASX:PEB -3.85% 42 EBITDA is A$-32.03 Mil as of Mar. 2026. GuruFocus rates ASX:PEB with a GF Score™ of 42/100 and a GF Value™ of A$0.05 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Pacific Edge's EBITDA for the six months ended in Mar. 2026 was A$-13.92 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was A$-32.03 Mil.

During the past 3 years, the average EBITDA Growth Rate was -4.10% per year. During the past 5 years, the average EBITDA Growth Rate was -16.00% per year. During the past 10 years, the average EBITDA Growth Rate was -7.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Pacific Edge was 7.50% per year. The lowest was -50.40% per year. And the median was -17.35% per year.

Pacific Edge's EBITDA per Share for the six months ended in Mar. 2026 was A$-0.01. Its EBITDA per share for the trailing twelve months (TTM) ended in Mar. 2026 was A$-0.04.

During the past 3 years, the average EBITDA per Share Growth Rate was 0.80% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -11.10% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 1.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Pacific Edge was 21.40% per year. The lowest was -33.90% per year. And the median was -2.65% per year.

Pacific Edge  (ASX:PEB) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Pacific Edge EBITDA Related Terms


Pacific Edge EBITDA Historical Data

* Premium members only.

The historical data trend for Pacific Edge's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacific Edge EBITDA Chart

Pacific Edge Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.30 -30.50 -31.57 -28.87 -30.84

Pacific Edge Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.19 -14.43 -14.60 -18.10 -13.92

ASX:PEB vs TMO, DHR, IDXX: EBITDA Comparison

For the Diagnostics & Research subindustry, Pacific Edge's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacific Edge EV-to-EBITDA vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pacific Edge's EV-to-EBITDA falls into.


ASX:PEB
42GF Score
Pacific Edge Ltd ASX:PEB
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Pacific Edge's EBITDA for the fiscal year that ended in Mar. 2026 is calculated as

Pacific Edge's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Mar. 2026, Pacific Edge's EBITDA was A$-30.84 Mil.

Pacific Edge's EBITDA for the quarter that ended in Mar. 2026 is calculated as

Pacific Edge's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Mar. 2026, Pacific Edge's EBITDA was A$-13.92 Mil.

EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-32.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of A$-32.03 Mil mean?
Pacific Edge (ASX:PEB) has a EBITDA of A$-32.03 Mil as of Mar. 2026. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Pacific Edge.
Is Pacific Edge's EBITDA too high?
Pacific Edge's current EBITDA is A$-32.03 Mil. Overall, Pacific Edge has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Edge's EBITDA compare to TMO and DHR?
Pacific Edge's EBITDA of A$-32.03 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Medical Diagnostics & Research company?
A good EBITDA depends on the Medical Diagnostics & Research industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Pacific Edge. Pacific Edge's current EBITDA is A$-32.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Edge stock overvalued right now?
Based on GuruFocus' analysis, Pacific Edge (ASX:PEB) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.25 — trading 400% above its estimated fair value. The current EBITDA is A$-32.03 Mil. Pacific Edge's overall GF Score™ is 42/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Pacific Edge (ASX:PEB), the current EBITDA is A$-32.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Edge (ASX:PEB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Edge stock appears to be overvalued. The current stock price of A$0.25 is trading 400% above its estimated GF Value™ of A$0.05. GuruFocus considers Pacific Edge to be Significantly Overvalued.

Key valuation signals for ASX:PEB:

  • EBITDA: A$-32.03 Mil
  • GF Value™: A$0.05 vs. price of A$0.25 (400% above fair value)
  • GF Score™: 42/100 with 8 warning signs

No single metric tells the full story. See the ASX:PEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacific Edge Business Description

Address 87 Saint David Street, P.O. Box 56, Dunedin, STL, NZL, 9016
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
42GF Score

Get the complete analysis for ASX:PEB

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.25
Price
A$0.05
GF Value